
ITRM Stock Forecast & Price Target
ITRM Analyst Ratings
Bulls say
Iterum Therapeutics PLC is positioned favorably due to significant clinical improvements demonstrated by its product, Orlynvah, particularly in the quinolone-resistant patient population, where a 26% and 34% enhancement in overall response was noted at key treatment time points. The favorable safety profile of sulopenem distinguishes it in the competitive landscape of antibiotics, positioning it as a potential first choice for treating complicated urinary tract infections in at-risk populations, such as adult women. These factors contribute to the belief that Iterum's stock is undervalued, with potential for significant upside in the near term as the company continues to leverage its commercial opportunities.
Bears say
Iterum Therapeutics is facing a negative outlook primarily due to depressed forward multiples amid ongoing market volatility, which raises concerns about investor confidence. Additionally, while cash burn could fluctuate based on pre-commercial activities and potential revenue from partnerships, the uncertainty surrounding these factors adds to risk. Moreover, the increasing prevalence of antibiotic-resistant bacteria presents a significant challenge, potentially limiting the demand for effective treatment options such as Orlynvah.
This aggregate rating is based on analysts' research of Iterum Therapeutics Plc and is not a guaranteed prediction by Public.com or investment advice.
ITRM Analyst Forecast & Price Prediction
Start investing in ITRM
Order type
Buy in
Order amount
Est. shares
0 shares